HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study.

[1]  O. Ojurongbe,et al.  Occult Hepatitis B Virus Infection among HIV Positive Patients in Nigeria , 2014, Journal of tropical medicine.

[2]  S. Cole,et al.  Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009 , 2013, Journal of acquired immune deficiency syndromes.

[3]  R. Detels,et al.  Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China. , 2013, The Journal of infectious diseases.

[4]  S. Nanta,et al.  Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Taisheng Li,et al.  Immunological and virological responses to combined antiretroviral therapy in HIV/hepatitis B virus-coinfected patients from a multicenter cohort , 2012 .

[6]  L. Taylor,et al.  HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  S. Cole,et al.  Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010 , 2012, PloS one.

[8]  David P. Wilson,et al.  HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis , 2012, BMC Infectious Diseases.

[9]  D. Jamieson,et al.  HIV-HBV coinfection--a global challenge. , 2012, The New England journal of medicine.

[10]  P. Easterbrook,et al.  Challenges and Priorities in the Management of HIV/HBV and HIV/HCV Coinfection in Resource-Limited Settings , 2012, Seminars in Liver Disease.

[11]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[12]  Shuntai Zhou,et al.  Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. , 2011, The Lancet. Infectious diseases.

[13]  Shen-Ying Zhang,et al.  Association of Genetic Variation in Il28B with Hepatitis C Treatment-Induced Viral Clearance in the Chinese Han Population , 2011, Antiviral therapy.

[14]  Shuntai Zhou,et al.  Eff ect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China : a national observational cohort study , 2011 .

[15]  R. Barth,et al.  Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[16]  Zunyou Wu,et al.  Development of a unified web-based national HIV/AIDS information system in China , 2010, International journal of epidemiology.

[17]  Ning Wang,et al.  HIV-Infected Former Plasma Donors in Rural Central China: From Infection to Survival Outcomes, 1985–2008 , 2010, PloS one.

[18]  M. Núñez,et al.  Clinical syndromes and consequences of antiretroviral‐related hepatotoxicity , 2010, Hepatology.

[19]  J. Sterne,et al.  Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes , 2010, The Lancet.

[20]  L. Finelli,et al.  Trends in Hepatitis C Virus Infection Among Patients in the HIV Outpatient Study, 1996–2007 , 2010, Journal of acquired immune deficiency syndromes.

[21]  P. Chiliade,et al.  Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[23]  Ray Y. Chen,et al.  Five-Year Outcomes of the China National Free Antiretroviral Treatment Program , 2009, Annals of Internal Medicine.

[24]  V. Sharp,et al.  Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. , 2008, World journal of gastroenterology.

[25]  Gui Xi-en,et al.  Interaction of hepatitis B and C viruses in patients infected with HIV. , 2008, Journal of acquired immune deficiency syndromes.

[26]  M. Newell,et al.  Hepatitis B or hepatitis C coinfection in HIV‐infected pregnant women in Europe , 2008, HIV medicine.

[27]  S. Pol,et al.  Co-infection par le virus de l’immunodéficience humaine et le virus de l’hépatite C , 2008 .

[28]  M. Sulkowski,et al.  Viral hepatitis and HIV coinfection. , 2008, Journal of hepatology.

[29]  S. Pol,et al.  [HIV and hepatitis C virus coinfection]. , 2008, Gastroenterologie clinique et biologique.

[30]  V. Soriano,et al.  Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. , 2007, The Journal of infectious diseases.

[31]  G. Dore,et al.  Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database , 2007, Journal of gastroenterology and hepatology.

[32]  M. Chevallier,et al.  Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  C. Thio,et al.  Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. , 2007, The Lancet. Infectious diseases.

[34]  O. Kirk,et al.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.

[35]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[36]  B. Ledergerber,et al.  Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from an Inter-Cohort Analysis , 2006, Antiviral therapy.

[37]  H. Sørensen,et al.  Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  I. Hurtado,et al.  Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART , 2006, AIDS.

[39]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[40]  K. Sabin,et al.  Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention , 2005, AIDS.

[41]  B. Gazzard,et al.  Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[43]  A. Mocroft,et al.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort , 2005, AIDS.

[44]  J. Guest,et al.  Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Rockstroh,et al.  HIV and hepatitis C virus co-infection. , 2004, The Lancet. Infectious diseases.

[46]  K. Ruxrungtham,et al.  Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort , 2004, AIDS.

[47]  C. Hung,et al.  Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[49]  Richard D Moore,et al.  Hepatitis C and progression of HIV disease. , 2002, JAMA.

[50]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.